Astra Zeneca, D5010C00009, A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Outpatients with Early Alzheimer’s Disease; PAREXEL number 216846.
DEMENTIA TRIALS AUSTRALIA